Stem cell-based therapies for neuroretinal degeneration: current landscape and future perspectives
Stem Cells Translational Medicine · 20.07.2026 · 15 (8)
DOI: 10.1093/stcltm/szag046 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Stem Cells Translational Medicine, online erschienen am 27.07.2026. Verfasst von Sarah Saietz und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Sciences, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden. Hauptthemen laut MEDLINE: Retinal Degeneration, Stem Cell Transplantation, Stem Cells. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 86 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Promobilia Foundation, The Erling Person Foundation, The Knut and Alice Wallenberg Foundation.
Abstract (Originalsprache)
Retinal degenerations, comprising a heterogeneous group of disorders culminating in neuroretinal dysfunction, such as inherited retinal dystrophies (IRDs) and age-related retinal degeneration, are among the leading causes of irreversible vision loss worldwide. Restoring visual function through cell replacement therapy represents an attractive, yet challenging, strategy. Candidate retinal cell sources include retinal progenitor cells (RPCs), Müller glia, human neuroretinal stem-like cells (hNRSCs), and pluripotent stem cells (PSCs). In this review, we discuss their translational advantages and limitations, which in turn influence clinical implementation. We analyze critical manufacturing challenges, including GMP scalability, quality assurance, and ethical considerations in donor material sourcing. Experimental criteria for assessing cellular products’ integration into host circuitry and their capacity to restore visual function in preclinical retinal degeneration models must account for donor maturity, host retina architecture, and immune modulation, which determine survival, synapse connectivity, and delivery requirements. Ongoing clinical trials highlight the diversity of cell replacement strategies—from fetal-derived and allogenic progenitor suspensions to laminated PSC-derived retinal sheets—with each approach presenting distinct implications for survival, true integration, and logistical complexity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Clinical Sciences, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden.
- Gynecology and Reproductive Medicine, Karolinska University Hospital Huddinge, Stockholm, Sweden.
- Clinical Neuroscience, Section for Ophthalmology and Vision, Karolinska Institutet, St. Erik Eye Hospital, Stockholm, Sweden.
ORCID-Profile: Anders Kvanta
Förderung
- The Promobilia Foundation
- The Erling Person Foundation
- The Knut and Alice Wallenberg Foundation
- The Karolinska Institutet Foundation, and The ARMEC Lindeberg Foundation
Zitieren
APA
Saietz, S., Locri, F., Isla-Magrané, H., Mills, B., Lanner, F., & Kvanta, A. (2026). Stem cell-based therapies for neuroretinal degeneration: current landscape and future perspectives. Stem Cells Translational Medicine, 15(8). https://doi.org/10.1093/stcltm/szag046
Vancouver
Saietz S, Locri F, Isla-Magrané H, Mills B, Lanner F, Kvanta A. Stem cell-based therapies for neuroretinal degeneration: current landscape and future perspectives. Stem Cells Translational Medicine. 2026;15(8). doi:10.1093/stcltm/szag046
BibTeX
@article{Saietz2026,
author = {Saietz, Sarah and Locri, Filippo and Isla-Magrané, Helena and Mills, Brandon and Lanner, Fredrik and Kvanta, Anders},
title = {Stem cell-based therapies for neuroretinal degeneration: current landscape and future perspectives},
journal = {Stem Cells Translational Medicine},
year = {2026},
volume = {15},
number = {8},
doi = {10.1093/stcltm/szag046}
}
EUVIMED